Wednesday, October 13, 2021 1:28:25 PM
Marjac
Further .......
The defendants seek to bring the position adopted by A as to Rule 60 to support their assertions that the Epadi motions are untimely and without merit.This can simply be turned on its head:had A supported substantively or financially the Epadi action would the defendants have accepted the timely nature of the application(because it would still have been brought at the same time ?-would it have rendered the motion meritorious in the defendants view?
“ Epadi cropped table-Kool Aid “
By referring to such in their brief the defendants have clearly recognised Epadi assertion that the K table WAS cropped. Beyond this reference the defendants silence as to this crucial factual matter is defeaning.The defendants do not take their obvious opportunity to deny that the table WAS cropped.They do not seek to explain how this happened or whom was responsible for it. Above all and most significantly they do attempt to negate Epadi crucial point that the cropping of the table left out the most compelling information arising from the K study which was - NS- no statistical significance
Had the court read the missing element - the cropped element-NS - the court could only have concluded that the K study could not have rendered A patents obvious
The defendants silence speaks volumes as to their continued duplicity- for indeed they now have the opportunity to recognise the factual and statistical truth.
Cropping-leaving NS out allowed the defendants through evidence from their duplicitous experts testimony to completely misrepresent the K study to support a finding of obviousness
More to follow
Alm
Further .......
The defendants seek to bring the position adopted by A as to Rule 60 to support their assertions that the Epadi motions are untimely and without merit.This can simply be turned on its head:had A supported substantively or financially the Epadi action would the defendants have accepted the timely nature of the application(because it would still have been brought at the same time ?-would it have rendered the motion meritorious in the defendants view?
“ Epadi cropped table-Kool Aid “
By referring to such in their brief the defendants have clearly recognised Epadi assertion that the K table WAS cropped. Beyond this reference the defendants silence as to this crucial factual matter is defeaning.The defendants do not take their obvious opportunity to deny that the table WAS cropped.They do not seek to explain how this happened or whom was responsible for it. Above all and most significantly they do attempt to negate Epadi crucial point that the cropping of the table left out the most compelling information arising from the K study which was - NS- no statistical significance
Had the court read the missing element - the cropped element-NS - the court could only have concluded that the K study could not have rendered A patents obvious
The defendants silence speaks volumes as to their continued duplicity- for indeed they now have the opportunity to recognise the factual and statistical truth.
Cropping-leaving NS out allowed the defendants through evidence from their duplicitous experts testimony to completely misrepresent the K study to support a finding of obviousness
More to follow
Alm
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
